Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 302 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... June 12, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib July 28, 2020 A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... February 6, 2023 Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations October 10, 2018 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... ESMO Advocates for Equal Access to Optimal Cancer Care for all... Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With...
